E. Bourstyn
- Cancer Research top 5%
- Breast Cancer Treatment Studies 11
- Cancer Genomics and Diagnostics 5
-
- Breast Lesions and Carcinomas 9
- Genetic factors in colorectal cancer 3
- Oncology top 5%
- Cancer Treatment and Pharmacology 6
- HER2/EGFR in Cancer Research 3
- Cancer-related Molecular Pathways 3
- Hepatology top 10%
-
- Glycosylation and Glycoproteins Research 2
E. Bourstyn
28 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 74
- Cancer Research 637
- Pathology and Forensic Medicine 358
- Oncology 503
- Hepatology 65
- Genetics 156
Countries citing papers authored by E. Bourstyn
This map shows the geographic impact of E. Bourstyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Bourstyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Bourstyn more than expected).
Fields of papers citing papers by E. Bourstyn
This network shows the impact of papers produced by E. Bourstyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Bourstyn. The network helps show where E. Bourstyn may publish in the future.
Co-authorship network
The 25 scholars most cited alongside E. Bourstyn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 4 | |
| 2 | 2020 | 6 | |
| 3 | 2018 | 4 | |
| 4 | 2016 | 11 | |
| 5 | 2013 | 79 | |
| 6 | 2013 | 151 | |
| 7 | 2011 | 43 | |
| 8 | 2010 | 1 | |
| 9 | 2009 | 14 | |
| 10 | 2006 | 4 | |
| 11 | 2005 | 0 | |
| 12 | 2002 | 265 | |
| 13 | 2001 | 2 | |
| 14 | Detection of circulating MUC1-positive cells in breast cancer | 1999 | 2 |
| 15 | 1998 | 34 | |
| 16 | 1994 | 61 | |
| 17 | [Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast]. | 1993 | 4 |
| 18 | 1991 | 2 | |
| 19 | Anorexia in oesophageal carcinoma. | 1987 | 3 |
| 20 | 1983 | 40 |
About E. Bourstyn
E. Bourstyn is a scholar working on Cancer Research, Pathology and Forensic Medicine, Oncology, Otorhinolaryngology and Dermatology, having authored 30 papers that have together received 1.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (11 papers), Breast Lesions and Carcinomas (9 papers), Cancer Treatment and Pharmacology (6 papers), Cancer Genomics and Diagnostics (5 papers), Genetic factors in colorectal cancer (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer-related Molecular Pathways (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Cancer Research (637 citations), Pathology and Forensic Medicine (358 citations), Oncology (503 citations), Hepatology (65 citations) and Genetics (156 citations). E. Bourstyn has collaborated with scholars based in France, Sweden and Japan. Frequent co-authors include Anne Vincent‐Salomon, Jean-Marc Extra, Roman Rouzier, Marie-Christine Falcou, Bernard Asselain, Philippe Vielh, Jerzy Klijanienko, Marc Espié, P Pouillart and Alain Fourquet. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, British journal of surgery, Breast Cancer Research and Treatment and Radiotherapy and Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.